Abstract:Objective This study utilized the stimulated thyroglobulin (sTg) to thyroid stimulating hormone (TSH) ratio to predict the long-term efficacy of 131 I therapy in patients with moderate-to-high-risk differentiated thyroid cancer (DTC). Methods This study retrospectively analyzed 960 DTC patients with a median follow-up time of 30 months (6–92 months). The median age was 44 years. All patients underwent total thyroidectomy, lymph node dissection, and at least one 131 I therapy. Patients were subjected to a final efficacy evaluation according to American Thyroid Association’s 2015 guidelines. Patients were grouped according to their TSH levels before the initial 131 I therapy and the final efficacy evaluation, and factors influencing TSH levels and final efficacy were analyzed. Construction of nomograms using independent risk factors affecting long-term outcomes. The cut-offs of sTg and sTg/TSH ratios were calculated for different long-term outcomes. Progression-free survival (PFS) of patients was analyzed by making Kaplan-Meier survival according to the cut-offs of sTg and sTg/TSH ratio. Results TSH (mU/L) levels were more concentrated at 60–90 in females (71.5%) and 30–60 in males (39.0%), while patients with younger age, more lymph node metastases, shorter time interval between surgery and the first 131 I therapy, and lower dose of levothyroxine sodium taken prior to the first 131 I therapy would have higher TSH levels (All P < 0.05).Patients who are male, have primary tumor involvement of the strap muscles, lymph node metastasis, distant metastasis, and higher sTg and sTg/TSH are more likely to have poor long-term outcomes (All P < 0.05).The cut-offs of sTg and sTg/TSH for long-term efficacy were 7.515 and 0.095. STg, sTg/TSH, tumor size, lymph node metastasis, and distant metastasis were shown to be independent risk factors for long-term efficacy. The mean PFSs were longer for patients who had sTg/TSH ≤ 0.095 and/or sTg≤7.515 ug/L. Conclusions For patients with moderate-to-high-risk DTC, when sTg>7.515 ug/L and/or sTg/TSH > 0.095 before the first 131 I therapy, patients are more likely to have a poor long-term efficacy after full 131 I therapy. This means that this group of patients may require further surgical treatment or targeted drug therapy after 131 I therapy.

Bone Turnover Markers in Patients with Differentiated Thyroid Carcinoma after Levothyroxine Withdrawal

Body composition changes in patients with differentiated thyroid cancer after iodine-131 treatment and short-term levothyroxine replacement and suppression therapy

Change of Serum TSH and FT_4 after Thyroxine Withdrawal in Differential Thyroid Carcinoma

Changes of Related Serum Hormone Levels after Operation or Withdrawal of Drug Substitution Treatment in Patients with Differentiated Thyroid Carcinoma

Blood Lipids in Patients with Differentiated Thyroid Carcinoma on Suspension of Hormone Replacement Therapy

Transiently impaired endothelial function during thyroid hormone withdrawal in differentiated thyroid cancer patients

The relationships between thyroid functions of short-term rapid hypothyroidism and blood lipid levels in post-thyroidectomy patients of differentiated thyroid cancer

Analysis of liver function, serum lipid and blood routine in patients with differentiated thyroid cancer before radioactive iodine treatment

[The Effects of Levothyroxine Replacement Therapy on Bone and Mineral Metabolism in Patients with Hypothyroidism].

Short-term hypothyroidism transiently impaired endothelial function in differentiated thyroid cancer patients

Predictive value of bone turnover markers and thyroid indicators for bone metabolism in GD patients after treatment

The Risk Between Thyrotropin Suppression and Bone Mineral Density in Differentiated Thyroid Cancer

Effect of Combination of ~(131)I and L-thyroxin on Bone Metabolism in Patients with Differentiated Thyroid Carcinoma after Surgery

EFFECTS OF LEVOTHYROXINE ON BONE METABOLISM IN PATIENTS WITH DIFFERENTIATED THYROID CANCER AFTER OPERATION AND ^131I ABLATION

Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study

Comparison of Bone Mineral Density and Trabecular Bone Score in Patients with and without Vertebral Fractures and Differentiated Thyroid Cancer with Long-Term Serum Thyrotrophin-Suppressed Therapy

Comparison of I-131 Biokinetics after Recombinant Human TSH Stimulation and Thyroid Hormone Withdrawal Measured by External Detector in Patients with Differentiated Thyroid Cancer

The effects of recombinant human TSH on bone turnover in patients after thyroidectomy

Analysis on Correlation of Thyroglobulin with 131-Iodine Whole Body Scan in Differentiated Thyroid Carcinoma Patients after Thyroid Ablation

Stimulating Thyroglobulin to TSH Ratio Predict Long-Term Efficacy of 131 I Therapy in Patients with Differentiated Thyroid Cancer after Total Thyroidectomy: a Retrospective Study

The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer